Atrial Natriuretic Peptide (ANP), rat: Molecular Mechanisms and Benchmarks in Cardiovascular and Renal Research

Executive Summary: Atrial Natriuretic Peptide (ANP), rat is a 28-amino acid peptide hormone (C₄₉H₈₄N₂₀O₁₅S, MW 1225.38) synthesized by atrial myocytes in response to atrial distension and neurohumoral stimuli (APExBIO). ANP acts as a potent vasodilator and natriuretic agent, regulating blood pressure and extracellular fluid homeostasis (see coverage). The A1009 product from APExBIO provides ≥95.92% purity (HPLC/mass spectrometry), enabling reproducible research in rodent models. ANP exerts its effects through cyclic GMP signaling and plays a secondary role in adipose tissue metabolism. This article presents atomic, evidence-based claims for cardiovascular and renal physiology studies.

Biological Rationale

Atrial Natriuretic Peptide (ANP), rat is a member of the natriuretic peptide family. It is produced, stored, and secreted by cardiac atrial myocytes, primarily in response to increases in atrial wall stretch, circulating angiotensin II, endothelin, and sympathetic nervous system activation (APExBIO). Upon release, ANP acts as a systemic hormone, targeting vasculature, kidneys, and adipose tissue.

ANP is evolutionarily conserved across mammalian species, with the rat peptide sequence: H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH. The peptide modulates sodium and water excretion (natriuresis, diuresis), vascular resistance, and lipid metabolism. This mechanism is critical for maintaining blood pressure and extracellular fluid volume within physiological ranges. Deficiency or dysregulation of ANP is implicated in hypertension, heart failure, and metabolic disorders (see mechanistic insights).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

Upon secretion, ANP binds to natriuretic peptide receptor-A (NPR-A), a guanylyl cyclase-coupled receptor. This activates intracellular cyclic guanosine monophosphate (cGMP) pathways, leading to smooth muscle relaxation and vasodilation (see precision tool). In the kidney, ANP increases glomerular filtration rate and inhibits sodium reabsorption in the distal convoluted tubule and collecting duct. This results in natriuresis and diuresis, reducing blood volume and systemic arterial pressure.

ANP also inhibits renin and aldosterone secretion, further suppressing the renin–angiotensin–aldosterone system (RAAS). In adipose tissue, ANP promotes lipolysis and modulates adiponectin secretion, influencing systemic metabolic homeostasis. These effects are concentration-dependent and require precise dosing, as provided by the ≥95.92% pure A1009 product (APExBIO).

Evidence & Benchmarks

• ANP administered intravenously to rats at 1–10 μg/kg produces rapid, dose-dependent reductions in systolic blood pressure within 5–10 minutes (Zhang et al., https://doi.org/10.21203/rs.3.rs-2117207/v1).
• ANP increases urinary sodium excretion by up to 350% over baseline in Sprague Dawley rats within 30 minutes post-injection (Zhang et al., https://doi.org/10.21203/rs.3.rs-2117207/v1).
• ANP inhibits renin and aldosterone release, resulting in decreased plasma renin activity and aldosterone concentrations (see mechanisms and research for further details).
• ANP modulates adipose tissue metabolism, increasing circulating adiponectin and enhancing lipolysis (Zhang et al., https://doi.org/10.21203/rs.3.rs-2117207/v1).
• The A1009 kit achieves ≥95.92% purity (validated by HPLC and MS), ensuring consistent, contaminant-free dosing in rodent studies (APExBIO).

This article extends prior work by integrating updated peer-reviewed benchmarks with direct product performance metrics, surpassing the protocol focus of this workflow guide.

Applications, Limits & Misconceptions

ANP is widely used as a reference vasodilator and natriuretic agent in cardiovascular, renal, and metabolic disease modeling. Common applications include:

• Acute blood pressure regulation studies in rodent models.
• Quantification of natriuretic response in renal physiology.
• Assessment of adipose tissue signaling and adiponectin modulation.
• Pharmacological benchmarking against hypertensive and heart failure drugs.

For a comprehensive analysis of ANP's vasodilatory spectrum, see this advanced review, which this article updates with new purity and workflow data.

Common Pitfalls or Misconceptions

• ANP is not effective in chronic hypertension models lacking functional NPR-A receptors.
• Long-term storage of ANP solutions (>2 weeks) at > -20°C leads to peptide degradation and loss of activity.
• ANP is insoluble in ethanol and must be prepared in DMSO (≥122.5 mg/mL) or water (≥43.5 mg/mL) for experimental use.
• Non-specific effects may arise if dosing exceeds 10 μg/kg in rodents, leading to hypotension and off-target actions.
• ANP should not be used as a sole marker for cardiac function; results must be integrated with other physiological parameters.

Workflow Integration & Parameters

APExBIO’s Atrial Natriuretic Peptide (ANP), rat (A1009) is supplied as a lyophilized solid. For solution preparation, dissolve at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in sterile water. Ethanol is unsuitable as a solvent. Store aliquots at -20°C and avoid repeated freeze-thaw cycles. Use prepared solutions promptly to maintain bioactivity.

Experimental protocols typically employ single or repeated intravenous or intraperitoneal injections in rats, at 1–10 μg/kg per administration. Control for peptide purity and solvent effects by including vehicle-only groups. For detailed stepwise workflows and troubleshooting, refer to the in-depth guide here.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat is an essential tool for dissecting the molecular and systemic mechanisms of cardiovascular, renal, and metabolic regulation. APExBIO’s A1009 product, with validated high purity, ensures experimental rigor and reproducibility. As research advances into the interplay between natriuretic peptides, adiponectin, and neuroimmune signaling, the precise deployment of ANP in rodent models will remain pivotal. For the latest product specifications and batch validation, consult the Atrial Natriuretic Peptide (ANP), rat product page.